Home > Haematology > EHA 2019 > Lymphoid Malignancies > Obinutuzumab/polatuzumab in follicular lymphoma

Obinutuzumab/polatuzumab in follicular lymphoma

Presented By
Prof. Wojciech Jurczak, Jagiellonian University, Poland
EHA 2019
Prof. Wojciech Jurczak (Jagiellonian University, Poland) presented the history of trials in high-risk relapsed/refractory follicular lymphoma (FL), focussing on a pre-planned interim analysis of a recent phase 1b/2 study [1,2]. This open-label, single-arm trial assessed the safety and preliminary efficacy of polatuzumab vedotin in combination with obinutuzumab and lenalidomide (Pola-G-Len) in patients with relapsed/refractory FL (n=52). Polatuzumab vedotin is a first-in-class antibody-drug conjugate that targets CD76b, a protein expressed in FL and diffuse large B cell lymphoma (DLBCL). Polatuzumab vedotin in combination with rituximab and bendamustine was recently approved for the treatment of relapsed or refractory DLBCL. The primary efficacy endpoint of the trial was complete response (CR) at the end of induction treatment, as assessed by an independent r...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on